LEPR
ENSG00000116678
Target class
Unclassified protein
Chromosome
1
Approved drugs
1
Clinical candidates (approved and in development)
2
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Target name
- LEPR
- Gene name
- Leptin receptor
- Gene symbol
- LEPR
- Protein name
- Leptin receptor (LEP-R) (HuB219) (OB receptor) (OB-R) (CD antigen CD295)
- OBR
- CD295
- LEP-R
- OB-R
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Immunoglobulin like domain containing
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 48
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 24.92
- Tissue specificity (Gini)
- 0.484
- Tissue specificity (tau)
- 0.812
- KEGG gene identifiers
- hsa:3953
- Protein interaction confidence
- 0.805393
- Protein interaction partners
- 56
- End position
- 65641559
- Start position
- 65420652
- Chromosome
- 1
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein . Basolateral cell membrane .
- SUBCELLULAR LOCATION: [Isoform E]: Secreted .
- Basal body
- Cytosol
- Plasma membrane
- Primary cilium
- Vesicles
Publication evidence
- PubMed 19159218
- Tissue specificity (tau)
- 0.811752
- Expression inequality (Gini)
- 0.4842
Expression in transcripts per million
- Nerve - Tibial
- 24.92
- Ovary
- 16.09
- Lung
- 13.15
- Breast - Mammary Tissue
- 12.94
- Uterus
- 11.86
Expression in transcripts per million
- Nerve - Tibial24.92
- Ovary16.09
- Lung13.15
- Breast - Mammary Tissue12.94
- Uterus11.86
- Cervix - Endocervix11.75
- Liver11.44
- Adipose - Visceral (Omentum)10.03
- Artery - Coronary9.57
- Cervix - Ectocervix9.55
- Thyroid8.78
- Artery - Tibial8.45
- Fallopian Tube8.42
- Adipose - Subcutaneous8.07
- Minor Salivary Gland7.39
- Cells - Cultured fibroblasts6.96
- Artery - Aorta6.67
- Stomach6.66
- Prostate4.9
- Esophagus - Gastroesophageal Junction4.9
- Skin - Not Sun Exposed (Suprapubic)4.83
- Bladder4.8
- Esophagus - Muscularis4.51
- Vagina4.12
- Pituitary3.89
And 29 more, listed on the interactive page.
- GO:0001525
- GO:0006112
- GO:0007166
- GO:0007275
- GO:0010507
- GO:0033210
- GO:0051049
- GO:0097696
- GO:0005886
- GO:0016323
- GO:0043235
- GO:0004888
- GO:0005515
- GO:0017046
- GO:0038021
Related records
Trials (37)
- A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults
- A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide
- A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
- A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
- A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects
- A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)
- A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects
- A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers
- A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea
- Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
- CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy
- Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
- Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
- Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance
- Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy
- Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)
- Expanded Access for Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
- Expanded Access Metreleptin Study
- Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling
- Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin
Drugs (2)
- Metreleptin Leptin receptor agonist
- Mibavademab Leptin receptor agonist